+1-888-308-5802     
News Contact Us

Phase II/III trials of gantenerumab fail to reach primary endpoint

Author : Saipriya Iyer | Published Date : 2020-02-10 

Genentech, a subsidiary of the Roche group, has recently announced that the Phase II/III DIAN-TU-001 clinical trial for gantenerumab failed to achieve the primary endpoint. The trial of this late-stage investigational medicine was conducted for treatment of patients suffering from early onset and inherited form of AD (Alzheimer’s disease), also known as ADAD (autosomal dominant AD), which accounts for less than 1% of AD cases. The Washington University School of Medicine has sponsored the clinical study.

In the trial, no significant slowdown in the rate of cognitive decline among patients provided with gantenerumab was observed as compared to placebo, measured using the DIAN Multivariate Cognitive Endpoint. The investigational medicine has been maintaining a safety profile consistent with other trials with no new issues being identified.

Roche and Genentech, in collaboration with the Washington University School of Medicine are currently focused on understanding and interpreting the gantenerumab data through additional analyses. In April 2020, the companies are expected to present the collected data at the AAT-AD/PD™ Focus meeting.

The companies’ AD pipelines consist of investigational drugs for various types, targets, and stages of Alzheimer’s disease. Apart from the gantenerumab trials, they are currently examining semorinemab in Phase II trials for sporadic AD. The Alzheimer’s Prevention Initiative Phase II trial in ADAD also includes the study of crenezumab.

Levi Garraway, Global Product Development’s chief medical officer and head, as well as others involved in the clinical study expressed their anticipation of data’s contribution towards understanding the complexities of AD. The study marks the bold undertaking towards treating AD, despite inability to reach primary endpoint. Dr. Garraway also commented on the team’s unwavering confidence in the ongoing Phase III clinical program.

Gantenerumab, is also being studied in GRADUATE 1 and 2, two large global Phase III trials among populations with sporadic AD, which is not caused by gene mutations. ADAD patients in the DIAN-TU-001 trial were initially treated with a lower dose of gantenerumab and started titrating to a 5x higher target dose only around midway through the study period.

Source credit:

https://www.gene.com/media/press-releases/14837/2020-02-09/genentech-provides-topline-results-from-

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

UK banks developing code of conduct on defaulting business loans

Published Date: 2020-07-07         Author: Saipriya Iyer

UK banks are reportedly developing a code of conduct for businesses who have defaulted on the coronavirus loans which are taxpayer-backed. According to industry estimates, around 8 out of 10 borrowers may not be able to repay the loans in full amount. UK Finance and British Business Bank were rep... Read More

Discord gaming app to become a general-purpose communications platform

Published Date: 2020-07-02         Author: Saipriya Iyer

Discord application, which was originally launched with a focus on video games, has reportedly announced that it is planning to emerge into a more general-purpose communications platform. Jason Citron, the Founder and CEO of Discord, has stated that the company’s original branding did not s... Read More

Amazon to offer 20,000 temporary or seasonal employment opportunities

Published Date: 2020-06-29         Author: Saipriya Iyer

Amazon has recently stated that it will offer nearly 20,000 temporary or seasonal employment opportunities in its CS (customer service) organization. This will enable the company to offer a seamless shopping experience for users in India and across the globe. These temporary job opportunities wer... Read More

© 2020 Fractovia. All Rights Reserved